Juhienah Khalaf | Director of Chemistry
Inimmune Corporation

Juhienah Khalaf specializes in building adjuvant portfolios and has designed and developed TLR4 and TLR7/8 agonists for use as vaccine adjuvants. Drawing on her strong background in medicinal and organic chemistry, she has advanced adjuvant candidates in a chemistry, manufacturing, and controls (CMC) setting and collaborated with formulation and immunology teams to characterize their properties and immune profiles. Her research focuses on therapeutic molecules that modulate immune responses and combat infectious diseases. Her work encompasses the development of TLR4 and TLR7/8 agonists and antagonists as small-molecule drugs and immunotherapies. These efforts have contributed to novel adjuvant systems and targeted therapies designed to address critical treatment challenges and broaden access to innovative vaccine adjuvants. Notably, Juhienah synthesized INI-2002, a TLR4 agonist that became a lead component of Inimmune's Adjuvant Systems. This pioneering work will be featured at WVC Europe in Amsterdam on October 21st in a presentation titled "Innovative Adjuvants for Advancing Global Access", highlighting INI-2002's potential to enhance vaccine efficacy through targeted delivery systems that modulate immune responses.